Higher natural Ac-SDKP tracked with less fibrotic signaling in rodents

What is Ac-SDKP, and is it the same as TB-500?

Ac-SDKP is a four-amino-acid fragment of thymosin beta-4, and it is a different molecule from TB-500. The enzyme prolyl oligopeptidase cleaves Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro, also called goralatide and seraspenide) from the N-terminus of the parent protein.

TB-500 is the name internet vendors usually give to LKKTETQ, the seven-amino-acid actin-binding sequence and a much more commonly sold "thymosin beta-4 fragment." TB-500 comes from positions 17 through 23 of the same parent protein, not the N-terminal four residues, and it drives a different biological program: cell migration and blood vessel sprouting rather than the antifibrotic signaling associated with Ac-SDKP ^[4].

The distinction is the source of most of the confused coverage of Ac-SDKP. Forum threads and vendor pages routinely cite wound-healing and angiogenesis data as if they apply to Ac-SDKP, when those studies were run on TB-500 or on the intact 43-residue parent peptide ^[1]⁠^[2]⁠^[3]⁠^[5]. None of the studies behind these claims tested Ac-SDKP itself; they tested its molecular relatives. TB-500 is also distinct from its parent: TB-500 is not thymosin beta-4, and the two have separate evidence records.

Where does the anti-fibrotic claim for Ac-SDKP come from?

Much of the anti-fibrotic evidence for Ac-SDKP comes from ACE-inhibitor pharmacology, not from injecting the peptide. Ac-SDKP's best-established role is as a natural substrate of angiotensin-converting enzyme (ACE). ACE inhibitors, the well-studied blood pressure drugs, block the enzyme that normally degrades Ac-SDKP, so plasma levels of the peptide rise as a downstream consequence of taking one.

In the rodent cardiac and renal fibrosis research, elevated endogenous Ac-SDKP correlates with reduced fibrotic signaling through the TGF-beta/Smad pathway, largely in hypertensive or surgically injured animal hearts and kidneys. The mechanism is coherent and biologically interesting. It describes a peptide that accumulates as a byproduct of another drug's action, not a peptide dosed on its own as a bolus injection.

None of the studies cited for Ac-SDKP's effects tests the peptide given on its own as a bolus injection. The mechanism is real, and it still cannot be turned into a specific injection protocol without more direct evidence than exists.

Is there any evidence that Ac-SDKP helps hair growth?

No direct evidence connects Ac-SDKP to hair growth, and no scalp-tissue data exist. The hair claim holds that Ac-SDKP keeps hematopoietic stem cells in a quiescent state and, by extension, protects the stem cell niche of a hair follicle.

The idea follows the same pattern as the fibrosis claim. It is mechanistically plausible and built on bone marrow physiology, then extrapolated to scalp tissue with nothing linking the two.

Which molecules do the studies cited for Ac-SDKP test?

The strongest data cited for Ac-SDKP belong to the LKKTETQ actin-binding fragment and to full-length thymosin beta-4, not to Ac-SDKP. In human endothelial cell migration and chick aortic arch angiogenesis assays, the isolated 7-amino-acid LKKTETQ fragment performed nearly identically to the full parent molecule at roughly 50 nM, and peptides missing any part of that sequence were inactive ^[2].

In full-thickness rat wounds, thymosin beta-4 delivered topically or intraperitoneally increased reepithelialization by 42% at day 4 and 61% at day 7 versus saline, with two- to threefold greater keratinocyte migration ^[1]. The same synthetic 7-amino-acid fragment reproduced comparable wound-repair effects in diabetic and aged mouse models ^[3].

A structure-function review confirms LKKTETQ as the active angiogenic and migratory site of the parent molecule. The same review notes that the fragment lacks the N-terminal Ac-SDKP domain and its associated anti-inflammatory, anti-apoptotic activity ^[4]. The TB-500 fragment's own evidence stops at cell assays and animal models.

Has Ac-SDKP been tested in humans?

No controlled human evidence supports Ac-SDKP as an injected compound for fibrosis, cardiac protection, wound healing, or hair-related endpoints. The human data cited for Ac-SDKP go no further than full-length thymosin beta-4.

Phase 2 work summarized in a 2012 review found accelerated healing of stasis and pressure ulcers treated with full-length thymosin beta-4, on the order of about one month faster in patients who achieved healing ^[5]. That work tested the parent protein, not the fragment.

The most advanced controlled human trial for anything in this family is a small, early-terminated Phase 3 ophthalmic RCT of full-length thymosin beta-4 (RGN-259) in neurotrophic keratopathy. The trial enrolled 18 subjects: 60% of the treatment arm reached complete corneal healing at four weeks, versus 12.5% on placebo ^[6]. RGN-259 is the intact 43-residue protein given as an eye drop, a route and molecule with no direct bearing on subcutaneous Ac-SDKP. The full record for the parent protein is in what human trials of thymosin beta-4 show.

Real angiogenic and wound-repair activity exists for a related fragment and for the parent molecule, in rodents and in one small human eye trial. None of that wound-repair evidence comes from Ac-SDKP.

Do Ac-SDKP injection protocols match how the peptide was studied?

No. Subcutaneous Ac-SDKP protocols borrow numbers loosely from animal fibrosis research, which typically used continuous infusion or osmotic minipump delivery. Continuous delivery is a fundamentally different exposure pattern from a periodic bolus shot.

Even the rat wound-healing study delivered thymosin beta-4 topically or intraperitoneally, not by subcutaneous injection on a fixed schedule ^[1]. No pharmacokinetic profile for exogenous Ac-SDKP, bolus or otherwise, appears in the studies cited for its effects. Online doses, frequencies, and expected plasma half-lives for Ac-SDKP cannot be traced to any of those studies, so they are unsourced.

Short peptides of this size are generally cleared quickly from circulation, a plausible reason the existing animal models used continuous delivery.

Is injecting research-grade Ac-SDKP safe?

Long-term safety of Ac-SDKP in humans is uncharacterized. Reported side effects (injection-site reactions, headache, fatigue, flushing) come from anecdotal use rather than controlled trials.

Product quality adds a second layer of uncertainty on top of the missing efficacy data. Research-use-only Ac-SDKP carries contamination and mislabeling risk, and products are frequently substituted with the unrelated LKKTETQ fragment or with full-length TB4.

Ac-SDKP is also on the WADA prohibited list for competitive athletes, a regulatory fact independent of the efficacy question. What TB-500's banned status does and does not mean covers the same distinction for the related fragment.

What is still unknown about Ac-SDKP?

Ac-SDKP's open questions run from exposure to outcome:

• Efficacy. No registered or completed human RCT has tested the isolated Ac-SDKP tetrapeptide for fibrosis, cardiac protection, wound healing, or hair-related endpoints.
• Exposure. Whether a subcutaneous bolus injection reproduces the exposure pattern seen in ACE-inhibitor-driven endogenous elevation, or in animal minipump studies, is untested.
• Pharmacokinetics. The half-life and clearance of injected Ac-SDKP are unmeasured in the studies cited for its effects.
• Safety. Long-term human safety is uncharacterized, and the side effect reports are anecdotal.